Taiwan has introduced a four-year National Pharmaceutical Resilience Preparedness Program, supported by NT$24 billion (approximately US$755 million). This initiative was announced by President Lai Ching-te during a meeting of the Healthy Taiwan Promotion Committee. Its objective is to strengthen Taiwan’s pharmaceutical supply chain while supporting the development of Taiwan’s biomedical industry.
Why Taiwan Is Taking Action
In recent years, global pharmaceutical supply chains have become increasingly vulnerable due to geopolitical shifts, pandemics, and climate-related disruptions. Many countries, including the United States, the European Union, and Japan have begun reshoring pharmaceutical manufacturing and establishing strategic reserves of essential medicines.
Taiwan faces particular challenges. The country depends heavily on imported pharmaceuticals and active pharmaceutical ingredients (APIs). Global production of APIs is highly concentrated in a few regions, meaning disruptions, whether from pandemics, geopolitical tensions, or manufacturing issues, can quickly affect the availability of medicines.
Against this backdrop, Taiwan’s government is seeking to ensure that essential medicines remain available even during emergencies or supply disruptions.
Three Strategic Pillars
The new program focuses on three key areas to reinforce supply resilience and strengthen the biomedical industry.
1. Domestic production for domestic use
The government aims to support the local production of at least 50 key pharmaceuticals, including essential medicines such as insulin, antibiotics, vaccines, immunomodulators and oncology drugs. Policy subsidies, market incentives, and adjustments to National Health Insurance reimbursement mechanisms will help encourage local manufacturing and API production.
This approach is intended to ensure that Taiwan maintains the capacity to supply critical medicines during crises.
2. Building a smart monitoring and logistics system
Taiwan will establish a national Pharmaceutical Intelligent Logistics and Storage Center (PILLS Center). This system will integrate smart monitoring technologies to provide early warnings of drug shortages and improve supply coordination across the healthcare system.
By strengthening real-time monitoring and logistics, authorities hope to move from reactive shortage management toward proactive supply forecasting.
3. Strengthening the biomedical industry and global partnerships
Beyond healthcare security, the program is also positioned as an economic development strategy. Taiwan aims to strengthen its biomedical industry and become an indispensable partner in global pharmaceutical and medical device supply chains.
Through international cooperation, technology development, and industry investment, the initiative seeks to transform pharmaceutical resilience into long-term industrial growth.
What This Means for the Global Drug Supply Chain
Taiwan’s pharmaceutical resilience strategy reflects a broader global shift toward diversified and secure medical supply chains. For the life sciences sector, the policy may create new opportunities in several areas:
- Local API and drug manufacturing partnerships
- Technology transfer and advanced pharmaceutical production
- Supply chain collaboration across Asia, Europe, and the United States
- Increased investment in biomedical R&D and production capacity
As global healthcare systems continue to prioritise resilience, Taiwan’s new program signals a clear ambition: not only to secure domestic drug supply, but also to play a larger role in the global pharmaceutical landscape.
Author: Wai Theng Lee, Clinical Research Partnerships Manager
